Teva Pharmaceutical Industries (TEVA) Other Operating Expenses (2012 - 2026)

Teva Pharmaceutical Industries (TEVA) has reported Other Operating Expenses for 12 consecutive years, with $19.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Other Operating Expenses rose 575.0% year-over-year to $19.0 million; the trailing twelve-month figure through Jun 2026 stood at $18.0 million (up 350.0% YoY), and the FY2025 full-year result was -$18.0 million, down 228.57% from the prior year.
• Other Operating Expenses advanced to $19.0 million in Q2 2026 per TEVA's latest filing, from $9.0 million in the prior quarter.
• Across five years, Other Operating Expenses topped out at $52.0 million in Q1 2022 and bottomed at -$8.0 million in Q4 2024.
• Historically, Other Operating Expenses has averaged $10.0 million across 5 years, with a median of $4.0 million in 2022.
• The sharpest annual moves came in 2022 and 2025: Other Operating Expenses soared 940.0% in 2022, then plunged 400.0% in 2025.
• Over 5 years, Other Operating Expenses stood at $19.0 million in 2022, then sank by 68.42% to $6.0 million in 2023, then plunged by 233.33% to -$8.0 million in 2024, then soared by 62.5% to -$3.0 million in 2025, then soared by 733.33% to $19.0 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $19.0 million, $9.0 million, and -$3.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.